<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="and prevention of KSHV-associated diseases [20]. For example, treatment with" exact="Ganciclovir" post="(GCV) and Foscarnet (PFA) to block the viral DNA"/>
 <result pre="lytic replication, iSLK.219 cells were exposed to increasing concentrations of" exact="doxycycline" post="(Dox) (up to 4 μg/mL) and/or sodium butyrate (NaB)"/>
 <result pre="anti-KSHV drug screening. (A) The iSLK.219 cells were induced by" exact="doxycycline" post="(Dox) or sodium butyrate (NaB) alone or the combination,"/>
 <result pre="Virion productiona RFP expressionb Targets IC50d(μM) SIe IC50 (μM) SI" exact="Monobenzone" post="&amp;gt;360 0.72 &amp;gt;500 1.48 &amp;gt;243.2 Tyrosinase. Spironolactone 300 1.07"/>
 <result pre="IC50 (μM) SI Monobenzone &amp;gt;360 0.72 &amp;gt;500 1.48 &amp;gt;243.2 Tyrosinase." exact="Spironolactone" post="300 1.07 280 7.0 42.9 Corticosteroids. Oxibendazole 132.6 1.5"/>
 <result pre="6.7 53 10.6 34 Agonists of Muscarinic receptor and Nicotinic" exact="acetylcholine" post="receptor. Hycanthone 40 1.4 29.4 7.1 5.7 DNA topoisomerases."/>
 <result pre="Phenothiazine 103.8 4 26 - - Antagonists of Histamine receptors," exact="Dopamine" post="D2 receptor, Adrenergic α receptor, Serotonergic 2C receptor, and"/>
 <result pre="receptor, Adrenergic α receptor, Serotonergic 2C receptor, and Muscarinic receptor." exact="Paroxetine" post="30 1.4 21.3 13.3 2.3 Selective serotonin reuptake inhibitor."/>
 <result pre="and Adrenergic α1 receptor; Inhibiting reuptake of Serotonin and Norepinephrine." exact="Cyproheptadine" post="106.8 6.87 15.6 - - Antagonists of Histamine 1"/>
 <result pre="- Thioredoxin reductase. Fulvestrant 65 4.6 14.1 - - Steroid" exact="estrogen" post="receptor antagonist. Manidipine 55.2 4.2 13.1 - - Calcium"/>
 <result pre="Fulvestrant 65 4.6 14.1 - - Steroid estrogen receptor antagonist." exact="Manidipine" post="55.2 4.2 13.1 - - Calcium and aldosterone antagonist."/>
 <result pre="of 15 hit compounds with anti-KSHV activities, Phenothiazine, Protriptyline and" exact="Cyproheptadine" post="(Fig 3A–3D), all exhibit overlapping inhibitory effects on histamine"/>
 <result pre="under non-cytotoxic concentrations. Our results indicated that all representative antagonists," exact="Pyrilamine" post="maleate salt (PMS, H1R antagonist), Burimamide oxalate (H2R/H3R antagonist),"/>
 <result pre="of histamine receptors. Compounds Antagonist classes CC50a(μM) IC50b(μM) SI c" exact="Pyrilamine" post="maleate salt Histamine H1 receptor &amp;gt;500 33.51 &amp;gt;14.9 Triprolidine"/>
 <result pre="c Pyrilamine maleate salt Histamine H1 receptor &amp;gt;500 33.51 &amp;gt;14.9" exact="Triprolidine" post="hydrochloride 226.2 19.47 11.61 Diphenhydramine hydrochloride 334.2 36.33 9.20"/>
 <result pre="Diphenhydramine hydrochloride 334.2 36.33 9.20 Diphenylpyraline hydrochloride 106.8 15.97 6.69" exact="Orphenadrine" post="hydrochloride 8.24 1.26 6.53 Famotidine Histamine H2 receptor &amp;gt;900"/>
 <result pre="&amp;gt;3 Lafutidine &amp;gt;900 306.9 &amp;gt;2.9 Ranitidine HCL &amp;gt;900 600 -" exact="Cimetidine" post="&amp;gt;900 666 - Burimamide oxalate Histamine H2 and H3"/>
 <result pre="include several inhibitors targeting a series of neurotransmitter receptors, including" exact="dopamine" post="receptors, adrenergic receptors, serotonin receptors, muscarinic receptors and histamine"/>
 <result pre="results indicate that some neurotransmitter receptors, such as adrenoreceptors and" exact="dopamine" post="receptors, can regulate KSHV reactivation through related signaling pathways"/>
 <result pre="latently infected with a recombinant rKSHV.219 virus and contain a" exact="doxycycline" post="(Dox)-inducible RTA, constructed and named by Dr. Don Ganem’s"/>
 <result pre="(TIF) LINK Click here for additional data file. S3 Fig" exact="Histidine" post="doesn’t promote KSHV lytic reactivation from iSLK.219 cells. The"/>
 <result pre="(2004) Remission of HHV-8 and HIV-associated multicentric Castleman disease with" exact="ganciclovir" post="treatment. Blood103: 1632–1634. 10.1182/blood-2003-05-172114615380 23SeifertR, StrasserA, SchneiderEH, NeumannD, DoveS,"/>
 <result pre="Clin Cancer Res24: 5085–5097. 10.1158/1078-0432.CCR-18-087330084838 31ChenJ, JiangL, LanK, ChenX (2015)" exact="Celecoxib" post="Inhibits the Lytic Activation of Kaposi's Sarcoma-Associated Herpesvirus through"/>
 <result pre="in hypertension. J Hypertens27: 680–691. 10.1097/HJH.0b013e32832810ed19516169 36VermaD, ThompsonJ, SwaminathanS (2016)" exact="Spironolactone" post="blocks Epstein-Barr virus production by inhibiting EBV SM protein"/>
 <result pre="et al. (2008) Regulation of Kaposi's sarcoma-associated herpesvirus reactivation by" exact="dopamine" post="receptor-mediated signaling pathways. J Acquir Immune Defic Syndr48: 531–540."/>
</results>
